Skip to main content

Advertisement

SpringerLink
Log in

Health-related quality of life and medication use among individuals with Angelman syndrome

  • Published:
Quality of Life Research Aims and scope Submit manuscript

Abstract

Purpose

The primary goal of this analysis is to describe the health-related quality of life (HRQoL), medical history, and medication use among adolescents and adults individuals with Angelman syndrome (AS).

Methods

The analysis uses baseline data collected during the STARS study, a double-blind placebo controlled trial of gaboxadol (OV101) in adolescents and adults with AS. The HRQoL was estimated using EuroQoL 5-Dimension 5-Level (EQ-5D) health questionnaire proxy 1 version, which was completed by the caregivers. EQ-5D consists of two parts, a 5-dimension descriptive and a visual analogue scale (VAS) component. The utility score derived from EQ-5D ranges from 0 to 1 (perfect health) and VAS ranges from 0 to 100 (perfect health).

Results

87 individuals with AS were included in the present analysis. The mean utility score was 0.44 ± 0.20 and VAS score was 84 ± 1.5. The EQ-5D data indicated that the self-care, mobility and daily activities were most impacted. All adolescents (100%) and most adults (93%) had at least moderate problems with self-care activities, such as washing or dressing themselves. More than half (55%) of the adolescents and adults had at least moderate issues with mobility and usual activities. Approximately, 30% of adolescents and adults had moderate to extreme problems with anxiety/depression. High baseline concomitant use of medications was observed across both age groups with an average of 5 medications being used per person.

Conclusion

This study highlights the impact of AS on HRQoL and medication utilization among adolescents and adults individuals with AS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

Ovid Therapeutics Inc (Ovid) is committed to providing qualified scientific researchers appropriate access to anonymized data and clinical study information from the company’s clinical trials for the purpose of conducting legitimate scientific research. Additionally, Ovid shall post all company-sponsored safety and efficacy studies of clinical trial participants on the clinical trial registries of the U.S. National Institutes of Health (NIH) and European Medicines Agency (EMA), as mandated by applicable laws and regulations. Ovid supports an approach to sharing data that responsibly reflects the interests of all parties involved in clinical trials, including protecting (i) the rights and privacy of trial participants, (ii) the innovator’s intellectual property rights, and (iii) other incentives for innovation, and as such, will evaluate requests for sharing company clinical trial data with qualified external scientific researchers. Data will be made available for request either (i) after product approval in the United States and European Union, (ii) after product development is discontinued or (iii) as otherwise required by law or regulation. There are circumstances that may prevent Ovid from sharing the requested data as the product is still investigational at this time.

Code availability

Not applicable.

References

  1. Williams, C. A., Beaudet, A. L., Clayton-Smith, J., Knoll, J. H., Kyllerman, M., Laan, L. A., Magenis, R. E., Moncla, A., Schinzel, A. A., Summers, J. A., & Wagstaff, J. (2006). Angelman syndrome 2005: updated consensus for diagnostic criteria. American Journal of Medical Genetics Part A, 140(5), 413–8.

    Article  PubMed  Google Scholar 

  2. Bindels-de Heus, K. G., Mous, S. E., ten Hooven-Radstaake, M., van Iperen-Kolk, B. M., Navis, C., Rietman, A. B., Ten Hoopen, L. W., Brooks, A. S., ENCORE Expertise Center for AS, Elgersma, Y., & Moll, H. A. (2020). An overview of health issues and development in a large clinical cohort of children with Angelman syndrome. American Journal of Medical Genetics Part A, 182(1), 53–63.

    Article  PubMed  Google Scholar 

  3. Buiting, K., Williams, C., & Horsthemke, B. (2016). Angelman syndrome - insights into a rare neurogenetic disorder. Nature Reviews. Neurology, 12(10), 584–593.

    Article  CAS  PubMed  Google Scholar 

  4. Bird, L. M. (2014). Angelman syndrome: Review of clinical and molecular aspects. The Application of Clinical Genetics, 7, 93–104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Guerrini, R., Carrozzo, R., Rinaldi, R., & Bonanni, P. (2003). Angelman syndrome: etiology, clinical features, diagnosis, and management of symptoms. Paediatric Drugs, 5(10), 647–661.

    Article  PubMed  Google Scholar 

  6. Tan, W. H., & Bird, L. M. (2016). Angelman syndrome: Current and emerging therapies in 2016. American Journal of Medical Genetics. Part C, Seminars in Medical Genetics, 172(4), 384–401.

    Article  CAS  PubMed  Google Scholar 

  7. Wheeler, A. C., Sacco, P., & Cabo, R. (2017). Unmet clinical needs and burden in Angelman syndrome: A review of the literature. Orphanet Journal of Rare Diseases, 12, 164.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Khan, N., Cabo, R., Tan, W. H., Tayag, R., & Bird, L. M. (2019). Healthcare burden among individuals with Angelman syndrome: Findings from the Angelman syndrome natural history study. Molecular Genetics & Genomic Medicine, 7(7), e00734.

    Article  Google Scholar 

  9. Griffith, G. M., Hastings, R. P., Oliver, C., Howlin, P., Moss, J., Petty, J., & Tunnicliffe, P. (2011). Psychological well-being in parents of children with Angelman, Cornelia de Lange and Cri du Chat syndromes. Journal of Intellectual Disability Research, 55(4), 397–410.

    Article  CAS  PubMed  Google Scholar 

  10. Willgoss, T., Cassater, D., Connor, S., Krishnan, M. L., Miller, M. T., Dias-Barbosa, C., Phillips, D., McCormack, J., Bird, L. M., Burdine, R. D., & Claridge, S. (2021). Measuring what matters to individuals with Angelman syndrome and their families: development of a patient-centered disease concept model. Child Psychiatry & Human Development. https://doi.org/10.1007/s10578-020-01051-z

    Article  Google Scholar 

  11. Larson, A. M., Shinnick, J. E., Shaaya, E. A., Thiele, E. A., & Thibert, R. L. (2015). Angelman syndrome in adulthood. American Journal of Medical Genetics Part A, 167A(2), 331–344.

    Article  PubMed  Google Scholar 

  12. Adams, D., Clarke, S., Griffith, G., Howlin, P., Moss, J., Petty, J., Tunnicliffe, P., & Oliver, C. (2018). Mental health and well-being in mothers of children with rare genetic syndromes showing chronic challenging behavior: A cross-sectional and longitudinal study. American Journal on Intellectual and Developmental Disabilities, 123(3), 241–253.

    Article  PubMed  Google Scholar 

  13. Grieco, J. C., Romero, B., Flood, E., Cabo, R., & Visootsak, J. (2019). Conceptual model of Angelman syndrome and review of relevant clinical outcomes assessments (COAs). Patient, 12(1), 97–112.

    Article  PubMed  Google Scholar 

  14. Khan, N., Cabo, R., Tan, W. H., Tayag, R., & Bird, L. M. (2019). An observational study of pediatric healthcare burden in Angelman syndrome: results from a real-world study. Orphanet Journal of Rare Diseases, 14, 239.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Thomson, A. K., Glasson, E. J., & Bittles, A. H. (2006). A long-term population-based clinical and morbidity profile of Angelman syndrome in Western Australia: 1953–2003. Disability and Rehabilitation, 28(5), 299–305.

    Article  CAS  PubMed  Google Scholar 

  16. Domínguez-Berjón, M. F., Zoni, A. C., Esteban-Vasallo, M. D., Sendra-Gutiérrez, J. M., & Astray-Mochales, J. (2018). Main causes of hospitalization in people with Angelman syndrome. Journal of Applied Research in Intellectual Disabilities, 31(3), 466–469.

    Article  PubMed  Google Scholar 

  17. Bird, L. M., Ochoa-Lubinoff, C., Tan, W. H., Heimer, G., Melmed, R. D., Rakhit, A., Visootsak, J., During, M. J., Holcroft, C., Burdine, R. D., & Kolevzon, A. (2021). The stars phase 2 study: A randomized controlled trial of gaboxadol in Angelman syndrome. Neurology. https://doi.org/10.1212/WNL.0000000000011409

    Article  PubMed  PubMed Central  Google Scholar 

  18. Herdman, M., Gudex, C., Lloyd, A., Janssen, M. F., Kind, P., Parkin, D., Bonsel, G., & Badia, X. (2011). Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research, 20(10), 1727–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Dolan, P. (1997). Modeling valuations for EuroQol health states. Medical Care, 35(11), 1095–1108.

    Article  CAS  PubMed  Google Scholar 

  20. Pickard, A. S., Law, E. H., Jiang, R., Pullenayegum, E., Shaw, J. W., Xie, F., Oppe, M., Boye, K. S., Chapman, R. H., Gong, C. L., & Balch, A. (2019). United States valuation of EQ-5D-5L health states using an international protocol. Value in Health, 22(8), 931–941.

    Article  PubMed  Google Scholar 

  21. Shaw, J. W., Johnson, J. A., & Coons, S. J. (2005). US valuation of the EQ-5D health states: Development and testing of the D1 valuation model. Medical Care, 43(3), 203–220.

    Article  PubMed  Google Scholar 

  22. Euroquol, G. (1990). EuroQol–a new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208.

    Article  Google Scholar 

  23. Janssen, B., & Szende, A. (2014). Population Norms for the EQ-5D. Self-Reported Population Health: An International Perspective based on EQ-5D, in Self-Reported Population Health: An International Perspective based on EQ-5D. Springer.

    Google Scholar 

  24. Jiang, R., Janssen, M. F. B., & Pickard, A. S. (2021). US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples. Quality of Life Research, 30(3), 803–816.

    Article  PubMed  Google Scholar 

  25. Chevreul, K., Gandré, C., Brigham, K. B., López-Bastida, J., Linertová, R., Oliva-Moreno, J., Serrano-Aguilar, P., Posada-de-la-Paz, M., Taruscio, D., Schieppati, A., & Iskrov, G. (2016). Social/economic costs and health-related quality of life in patients with fragile X syndrome in Europe. The European Journal of Health Economics, 17(Suppl 1), 43–52.

    Article  PubMed  Google Scholar 

  26. Cavazza, M., et al. (2016). Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe. The European Journal of Health Economics, 17(Suppl 1), 19–29.

    Article  PubMed  Google Scholar 

  27. Lin, J., Wong, C. K. H., Cheung, J. P. Y., Cheung, P. W. H., & Luo, N. (2022). Psychometric performance of proxy-reported EQ-5D youth version 5-level (EQ-5D-Y-5L) in comparison with three-level (EQ-5D-Y-3L) in children and adolescents with scoliosis. The European Journal of Health Economics, 23(8), 1383–95.

    Article  PubMed  Google Scholar 

  28. Takura, T., Koike, T., Matsuo, Y., Sekimoto, A., & Mutou, M. (2022). Proxy responses regarding quality of life of patients with terminal lung cancer: preliminary results from a prospective observational study. BMJ Open, 12(2), e048232.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Kelly, C., Hulme, C., Graham, L., Ellwood, A., Patel, I., Cundill, B., Farrin, A., Goodwin, M., Hull, K., Fisher, J., & Forster, A. (2021). Inter-rater reliability of care home staff’s proxy judgements with residents’ assessments of their own health-related quality of life: an analysis of the PATCH trial EQ-5D data. Age Ageing, 50(4), 1314–1320.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Fitriana, T. S., Purba, F. D., Stolk, E., & Busschbach, J. J. (2022). EQ-5D-Y-3L and EQ-5D-Y-5L proxy report: psychometric performance and agreement with self-report. Health and Quality of Life Outcomes, 20(1), 88.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Balboni, G., Coscarelli, A., Giunti, G., & Schalock, R. L. (2013). The assessment of the quality of life of adults with intellectual disability: The use of self-report and report of others assessment strategies. Research in Developmental Disabilities., 34(11), 4248–4254.

    Article  PubMed  Google Scholar 

  32. Lamsal, R., Finlay, B., Whitehurst, D. G., & Zwicker, J. D. (2020). Generic preference-based health-related quality of life in children with neurodevelopmental disorders: a scoping review. Developmental Medicine & Child Neurology, 62(2), 169–177.

    Article  Google Scholar 

  33. Péntek, M., Gulácsi, L., Brodszky, V., Baji, P., Boncz, I., Pogány, G., López-Bastida, J., Linertová, R., Oliva-Moreno, J., Serrano-Aguilar, P., & Posada-de-la-Paz, M. (2016). Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe. The European Journal of Health Economics, 17(Suppl 1), 89–98.

    Article  PubMed  Google Scholar 

  34. López-Bastida, J., Linertová, R., Oliva-Moreno, J., Posada-de-la-Paz, M., Serrano-Aguilar, P., Kanavos, P., Taruscio, D., Schieppati, A., Iskrov, G., Baji, P., & Delgado, C. (2016). Social/economic costs and health-related quality of life in patients with Prader-Willi syndrome in Europe. The European Journal of Health Economics, 17(Suppl 1), 99–108.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank the patients in the STARS study, their families and the STARS investigators and participating study centres. Statistical assistance in the preparation of this manuscript was provided by Maria Reynolds and Beth Sherrill at RTI Health Solutions. Beth Sherrill also reviewed and provided comments on the first draft of the manuscript. Financial support was from Ovid. Editorial support was provided by Shalaka Samant, Ph.D. from RWEC, LLC.

Funding

This study was funded by Ovid Therapeutics Inc, New York, NY, USA.

Author information

Authors and Affiliations

  1. RWEC, LLC, 73 Walsingham Road, Mendham, NJ, USA

    Nasreen Khan

  2. Ovid Therapeutics Inc, 441 Ninth Avenue, New York, NY, 10001, USA

    Raquel Cabo

  3. Department of Molecular Biology, Princeton University, 159 Moffett Laboratory, Washington Road, Princeton, NJ, 08544-1014, USA

    Rebecca D. Burdine

  4. Division of Genetics and Genomics: Harvard Medical School, Boston Children’s Hospital, 300 Longwood Avenue, Boston, MA, 02115, USA

    Wen-Hann Tan

  5. Angelman Syndrome Program, Lurie Center for Autism, Massachusetts General Hospital for Children, Harvard Medical School, One Maguire Road, Lexington, MA, 02421, USA

    Christopher J. Keary

  6. Division of Developmental-Behavioral Pediatrics, Rush University Medical Center, 1725 West Harrison Street, Suite 710, Chicago, IL, 60612, USA

    Cesar Ochoa-Lubinoff

  7. University of California, San Diego, Department of Pediatrics and Rady Children’s Hospital San Diego, Division of Dysmorphology/Genetics, 3020 Children’s Way #5031, San Diego, CA, 92123, USA

    Lynne M. Bird

Authors
  1. Nasreen Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raquel Cabo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rebecca D. Burdine
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wen-Hann Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christopher J. Keary
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Cesar Ochoa-Lubinoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lynne M. Bird
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

On behalf of the STARS Investigators

Contributions

All authors read and approved the final manuscript. All authors helped interpret the data and contributed to the manuscript. NK designed the analyses, interpreted the data and wrote the manuscript.

Corresponding author

Correspondence to Nasreen Khan.

Ethics declarations

Competing interests

Dr. Khan is a paid consultant for Ovid Therapeutics. Ms. Cabo is an employee of Ovid Therapeutics. Dr. Burdine consults on clinical trials supported by Ovid Therapeutics. Dr. Tan has participated in clinical trials supported by Ovid Therapeutics and Dimension Therapeutics and has also received research support from Ovid Therapeutics. Dr. Keary has consulted for Ovid Therapeutics and is participating in clinical trials supported by Ovid Therapeutics. Dr. Ochoa-Lubinoff has consulted for Ovid Therapeutics and participated in clinical trials supported by Ovid Therapeutics. Dr. Bird is participating in clinical trials supported by Ovid Therapeutics.

Ethical approval

Protocol approval and ethics oversight was provided by the regional IRBs/ECs at each site. Written informed consent was obtained from the legally authorized representative of each participating individual, prior to any study procedures.

Consent for publication

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Khan, N., Cabo, R., Burdine, R.D. et al. Health-related quality of life and medication use among individuals with Angelman syndrome. Qual Life Res 32, 2059–2067 (2023). https://doi.org/10.1007/s11136-023-03375-4

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11136-023-03375-4

Keywords

Search

Navigation